Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids

Paul Phillips; M. Verity; Tanya Wolfson
February 2009
Endocrine (1355008X);Feb2009, Vol. 35 Issue 1, p38
Academic Journal
Abstract  Despite exceptional efficacy and safety, fear of muscle toxicity remains a major reason statins are underutilized. Evidence suggests that statin muscle toxicity may be mediated by abnormalities in lipid metabolism. To test the hypothesis that myotubes from patients intolerant of lipid-lowering therapies have abnormal fatty acid oxidation (FAO) responses we compared muscle from 11 subjects with statin intolerance (Intolerant) with muscle from seven statin-naive volunteers undergoing knee arthroplasty (Comparator). Gross muscle pathology was graded and skeletal muscle cell cultures were produced from each subject. FAO was assessed following treatment with increasing statin concentrations. There was no difference in muscle biopsy myopathy scores between the groups. Basal octanoate oxidation was greater in Intolerant than in Comparator subjects (P = 0.03). Lovastatin-stimulated palmitate oxidation tended to be greater for Intolerant compared to Control subjects’ myotubes (P = 0.07 for 5 μM and P = 0.06 for 20 μM lovastatin). In conclusion abnormalities in FAO of Intolerant subjects appear to be an intrinsic characteristic of these subjects that can be measured in their cultured myotubes.


Related Articles

  • Comprehensive lipid management now possible.  // British Journal of Hospital Medicine (17508460);Sep2009, Vol. 70 Issue 9, p496 

    The article investigates the effectiveness of tredative in treating dyslipidaemia. It features the pharmacologic ingredients of tredative including laropiprant and nicotinic acid. In addition, it is considered as more effective in lipid management compared to statin monotherapy. It cites that...

  • pravastatin. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p622 

    A definition of the term "pravastatin" is presented. It refers to a lipid-lowering drug.

  • Pharmaceutical Treatment of Hypertension and Dyslipidemia in people With Diabetes: An Educator's Perspective Part 2: Dyslipidemia. Kruger, Davida F.; Cypress, Marjorie; Maryniuk, Melinda; Childs, Belinda P.; Tieking, Jody // Diabetes Spectrum;Spring2004, Vol. 17 Issue 2, p73 

    Part II. Discusses the pharmacological treatment of dyslipidemia. Evaluation of a case of a 49-year old man with dyslipidemia; Initial interventions for improving lipid profiles; Differences between lipid-lowering agents including statins, niacins, fibrates, bile acid sequestrants and...

  • Drugs for Children with Hypercholesterolemia: Be Cautious. Iughetti, Lorenzo // Journal of Pediatric Endocrinology & Metabolism;Jun2009, Vol. 22 Issue 6, p483 

    The author reflects on the use of statin drugs when treating children with hypercholesterolemia. He notes that the process of having atherosclerosis in adulthood starts in childhood where cholesterol lesions or fatty streaks are initially created. Lipid disorders like hypercholesterolemia play a...

  • Are high-potency statins in low dose 'strong statins'? Berent, Robert; Sinzinger, Helmut // Heart & Vessels;May2013, Vol. 28 Issue 3, p412 

    No abstract available.

  • HMG CoA reductase inhibitor-induced muscle toxicity: risks, monitoring, and management. White, C. Michael // Formulary;Nov2002, Vol. 37 Issue 11, p583 

    Discusses the muscle toxicity risk of the HMG CoA reductase inhibitors statins. Etiology of statin-associated muscle toxicity; Rhabdomyolysis; Drug monitoring.

  • Study clams GP fears on statins safety. Kelly, Brian // Pulse;6/10/2002, Vol. 62 Issue 23, p2 

    Deals with a study which examined the safety of lipid-lowering drugs statins. Medical conditions associated with statins; Drugs included in the study; Findings of the study.

  • Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease. Kurisu, Satoshi; Ishibashi, Ken; Kato, Yasuko; Mitsuba, Naoya; Dohi, Yoshihiro; Nishioka, Kenji; Kihara, Yasuki // Heart & Vessels;Jan2013, Vol. 28 Issue 1, p34 

    Residual risk of cardiovascular events after treatment with stain might be explained in part because patients have low levels of n−3 polyunsaturated fatty acids (PUFA). We examined how lipid-lowering therapy with strong statin affected serum PUFA levels in patients with coronary artery...

  • Triglycerides, HDL Cholesterol, and Other Secondary Targets of Lipid-Lowering Therapy. Bleidt, Barry; Ruisinger, Janelle R. // Pharmacy Today;Jul2006, Vol. 12 Issue 7, Special section p1 

    The article presents a special report from the American Pharmacists Association (APhA) concerning triglycerides, high density lipoproteins (HDL), and other indicators of lipid-lowering treatment. The causes of elevated serum triglycerides and the different approaches of its treatment are given....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics